On 1 January 2014, the American Company, Sequenom, was awarded the patent for MaterniT21 – the new screening test for Downs Syndrome. The test is based on a novel method that tests for chromosomal foetal abnormalities via genome sequencing. One blood sample is collected in the tenth week of pregnancy. The patent covers all European Union Member States as well as Lichtenstein, Monaco, Norway and Switzerland.
New test to screen for Downs Syndrome: Sequenom gets its patent
Publié le : 10 January 2014